Skip to main content

Mirum Pharmaceuticals

Mirum Pharmaceuticals Inc is an American biopharmaceutical company focused on developing and commercializing therapies for rare cholestatic liver diseases. The company offers commercial products including Livmarli for Alagille syndrome and progressive familial intrahepatic cholestasis, alongside Chenodal for cerebrotendinous xanthomatosis. Principal revenues are generated through commercial sales of its specialty prescription drugs to specialty pharmacies and international distributors. Core end markets consist of pediatric hepatology centers, rare disease clinics, and specialized tertiary hospitals worldwide. Mirum Pharmaceuticals holds a prominent position within the rare disease biopharmaceutical sector through its targeted oral liver disease pipeline. The company is headquartered in Foster City, California, and its common stock is traded on the Nasdaq Global Select Market.

8 of the funds FundTelligence covers report a position in Mirum Pharmaceuticals.

Legal name
Mirum Pharmaceuticals Inc
Sector
Health Care
Country
United States
Funds holding it
8

Funds holding Mirum Pharmaceuticals

Loading...